This study is currently not recruiting participants.

Comparison of composite lipid emulsion containing fish oil to soy-based lipid reduction for cholestasis prevention in neonates requiring abdominal surgery

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

Intravenous (or parenteral) nutrition is a necessary treatment for infants who cannot tolerate full feedings by mouth. The prolonged need for parenteral nutrition can lead to serious life threatening complications including liver damage, or intestinal failure associated liver disease (IFALD). Multiple strategies have been proposed to treat and prevent IFALD, but more information is still needed. Through this project we will compare two possible preventative treatment strategies including low does soy-lipid and a multi-component lipid, containing soy, MCT, olive, and fish oils (Smoflipid). This project will be a pilot study to better understand which (or both) strategies may benefit from further study in the future. Given this is a pilot study, we do not anticipate seeing a difference in our primary outcome of IFALD, but do anticipate some patients in the Smoflipid group will receive higher amount of calories and have greater rate of growth over time.

Description

Intravenous (or parenteral) nutrition is a necessary treatment for infants who cannot tolerate full feedings by mouth. The prolonged need for parenteral nutrition can lead to serious life threatening complications including liver damage, or intestinal failure associated liver disease (IFALD). Multiple strategies have been proposed to treat and prevent IFALD, but more information is still needed. Through this project we will compare two possible preventative treatment strategies including low does soy-lipid and a multi-component lipid, containing soy, MCT, olive, and fish oils (Smoflipid). This project will be a pilot study to better understand which (or both) strategies may benefit from further study in the future. Given this is a pilot study, we do not anticipate seeing a difference in our primary outcome of IFALD, but do anticipate some patients in the Smoflipid group will receive higher amount of calories and have greater rate of growth over time.

Details
Condition cholestasis
Age 100years or below
Clinical Study IdentifierTX8992
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.